Virbac: acquisition of Sasaeah in Japan
Sasaeah develops, manufactures and markets a broad portfolio of veterinary products for livestock and companion animals. It generates annual revenues of around €75 million, 50% of which come from vaccines, and has over 500 employees.
This transaction, which should be finalized in early April, will give Virbac a leading position in farm animal vaccines in Japan, particularly for cattle, and a broad portfolio of pharmaceutical products for all the main species.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction